Episode 201 - October 30, 2026

What It Covers

Biotech Hangout Episode 201 covers pharma M&A signals from Lilly, Bristol Myers, and Novartis; Anthropic's biotech expansion via two acquisitions; AI's realistic role in drug development; Alnylam's commercial struggles; IPO market momentum with 31 deals year-to-date; rare disease regulatory progress; and major oncology data from ESMO including Amgen's Delphi 305 small cell lung cancer results.

Key Questions Answered

• •Pharma M&A targeting: Lilly signals continued early and clinical-stage deal activity with explicit focus on immunology, neuroscience, and oncology. Bristol Myers holds $13B in cash and marketable securities with no deal-size preference. Novartis concentrates on bolt-on transactions below $2B. Investors should position pipeline assets in these three therapeutic areas to maximize acquisition interest heading into JPMorgan conference season.
• •AI's real bottleneck in drug development: AI meaningfully accelerates target identification, protein interaction modeling, and patient/site identification for trial enrollment — Amgen enrolled its Lp(a) study 16 months faster than Novartis using AI-driven informatics. However, outcome-based cardiovascular trials still require 5 years and $300M regardless of AI. Investors should weight AI value toward enrollment efficiency, not late-stage trial compression.
• •Anthropic entering drug development directly: Anthropic's S1 filing reveals two biotech acquisitions — computational biology firm Coefficient Bio and one-person startup Mithril Medicine. This signals that frontier AI companies are moving beyond tools into direct drug development. Biotech investors should monitor whether AI-native companies become pipeline competitors rather than just service providers to pharma and biotech.
• •Alnylam's commercial warning for platform biotechs: Alnylam's Amvutra US demand declined quarter-over-quarter despite a recent sales force expansion, triggering a second guidance cut this year and a 60% year-to-date stock decline. The lesson: strong clinical platforms and RNAi innovation do not guarantee commercial execution in competitive markets like ATTR. Biotechs should secure partnership or acquisition deals before attempting solo commercial launches.
• •IgA nephropathy treatment now stops disease progression: Otsuka's VOYZACT two-year phase 3 data published in the New England Journal of Medicine shows one kidney event on treatment versus 28 on placebo, with zero kidney replacement therapy cases versus five on placebo. Investors tracking the April/APRIL-BAFF target class should note Vertex's povitacept PDUFA date arriving within one month, with Climb Bio's CLB-116 as an earlier-stage watch.
• •Genmab closes its Darzalex royalty cliff with three concurrent data wins: Genmab reported three positive phase 3 datasets within weeks — epcoritamab frontline lymphoma showing 51% reduction in death/progression, rinatabart sesutecan ovarian cancer showing 60-70% reduction in deaths versus Elahere, and an undisclosed head-and-neck phase 3 showing 50% survival reduction regardless of HPV status. Analysts now model these three launches offsetting Darzalex royalty expiration in 2029-2030.